Stocks

Headlines

Eli Lilly Rated Strongly by Growth Investor Model at 88%

Eli Lilly shines with a strong 88% rating from the growth investor model, indicating solid fundamentals. Analysts show increased interest in this large-cap stock within the Biotechnology industry, suggesting potential for stock price growth.

Date: 
AI Rating:   7
Analysis of Eli Lilly's Performance

Eli Lilly and Co (LLY) has received commendable ratings based on the P/B Growth Investor model. With an impressive score of 88%, the stock is considered to have favorable fundamentals and valuations, especially given that scores above 80% indicate significant interest from investors.

The report highlights several critical factors that guide the model's assessment:

  • Book/Market Ratio: Pass - This suggests the stock is likely to be undervalued relative to its book value, which could attract more investors.
  • Return on Assets: Pass - A positive indicator of how efficiently the company is utilizing its assets.
  • Cash Flow from Operations to Assets: Pass - Indicates that the company is generating sufficient cash flow, supporting its operational stability.
  • Cash Flow from Operations to Assets vs. Return on Assets: Pass - Shows that operational cash flow is effectively generating return, reinforcing its investment quality.
  • Return on Assets Variance: Pass - Consistency in return on assets is a positive indicator for investors.
  • Sales Variance: Pass - Positive sales growth is essential for sustaining long-term valuation increases.
  • Advertising to Assets: Pass - Suggests that the company is effectively utilizing advertising to enhance sales.
  • Capital Expenditures to Assets: Pass - Indicates that proper investment is being made to maintain or grow the asset base.
  • Research and Development to Assets: Fail - While innovation is critical in the biotechnology sector, this failure suggests a potential area for concern. The company may be under-investing in R&D compared to its assets, which could impact future growth drivers.

Overall, Eli Lilly's high rating signifies a robust interest from the market. However, the failure in R&D investment is a cautionary aspect that investors should monitor as it could affect long-term growth prospects.

Stocks:  LLY